|

qEEG Brain Signature of Depression & Neuromodulation-induced Recovery

RECRUITINGPhase 1Sponsored by Sunnybrook Health Sciences Centre
Actively Recruiting
PhasePhase 1
SponsorSunnybrook Health Sciences Centre
Started2025-01-06
Est. completion2027-01-01
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted

Summary

This study aims to explore how repetitive transcranial magnetic stimulation (rTMS), a treatment for depression, affects brain function. Depression disrupts the brain's complex network or regions that regulate cognition, emotion, and behavior. rTMS targets these disruptions to restore network function. To measure these effects, researchers will use dry quantitative EEG (qEEG), a new technology that records brain electrical activity quickly (15 minutes compared to 1 hour for traditional EEG) without the need for gel or lengthy electrode setups. This study will evaluate a novel qEEG activity developed by iMediSync (Republic of South Korea) in patients treated with neuromodulation for depression before, during, and up to 12 months after treatment to see if changes in brain activity to identify patterns associated with symptomatic improvement and relapse risk. Findings could help personalize depression treatments by predicting patient outcomes and optimizing care.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* A diagnosis of Depression based on Diagnostic and Statistical Manual (DSM) 5.0 criteria.
* Receiving a neuromodulation (rTMS) treatment for depression at the HCN
* Physically healthy
* Age 18-80, inclusive.
* Able to provide informed consent and comply with the study protocol.
* Patients will not be excluded solely based on communication (i.e., non-English speaking) unless they have exclusion criteria that is the cause of the communication difficulties.

Exclusion Criteria:

* Moderate substance use disorder or greater severity based on DSM 5.0 criteria and confirmed by a study MD on clinical assessment.
* Mild and major comorbid medical conditions (as determined by investigators - e.g., neurological diseases, uncontrolled hypertension or diabetes, malignancy)
* A major comorbid psychiatric disorder (as determined by investigators - e.g., schizophrenia or bipolar disorder) and/or psychosis at the time of study enrollment.
* History of seizure disorder
* Pregnant

Conditions2

DepressionMajor Depressive Diorder

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.